Pacific Biosciences (PACB) 9.56 $PACB Coverage of

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 7:07 PM

Pacific Biosciences (PACB) 9.56 $PACB

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 14.59 (-0.46), PACB: 9.56 (-0.24), AVXL: 4.21 (-0.23), PPHM: 0.45 (-0.01)

What Caused Illumina's Shares to Crash 19% In April
Todd Campbell, The Motley Fool - Motley Fool - Thu May 05, 7:20AM CDT
SOURCE: ILLUMINA INC. What: After pre-announcing a revenue and profit shortfall, Illumina saw its shares lose 19.1% of their value last month, according to data from S&P Global Market Intelligence . So what: The maker of instruments...
PACB: 9.56 (-0.24), TMO: 151.80 (-2.35), ILMN: 141.62 (-1.80)

Pacific Biosciences and Advanced Analytical Technologies Announce Co-Marketing Agreement
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Pacific Biosciences of California, Inc., (Nasdaq

ACB) and Advanced Analytical Technologies, Inc., (AATI) today announced the companies have signed an agreement to jointly promote their technology solutions for long-read DNA sequencing.
PACB: 9.56 (-0.24)

Is Pacific Biosciences or Illumina Corp. a Better Buy?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 7:20AM CDT
SOURCE: ILLUMINA CORP. After reporting preliminary sales figures that were south of industry watchers' forecasts, shares in gene-sequencing giant Illumina Corp. toppled this week. Meanwhile, better-than-anticipated sales at Illumina's smaller...
PACB: 9.56 (-0.24), ILMN: 141.62 (-1.80)

Why Shares of Pacific Biosciences of California Spiked 19% Today
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 2:58PM CDT
The Sequel System. Image source: Pacific Biosciences. What: Shares of DNA sequencing company Pacific Biosciences of California jumped as much as 19% today after the company reported first-quarter earnings. So what: Revenue rose 8% from a...
PACB: 9.56 (-0.24)

Pacific Biosciences of California Pushing Toward Sustainable Growth
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 8:20AM CDT
First-quarter 2016 earnings from gene sequencer Pacific Biosciences of California were released after the market closed on Thursday, and the company's transition to sustainable long-term viability continued. The company launched the Sequel System...
PACB: 9.56 (-0.24)

Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 9.56 (-0.24), GMED: 24.63 (-0.54), INGN: 49.46 (-0.77), EXAC: 25.42 (+0.12)

Pacific Biosciences reports 1Q loss
Automated Insights - Thu Apr 21, 4:02PM CDT
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $19.4 million in its first quarter.
PACB: 9.56 (-0.24)

Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 3:00PM CDT
Pacific Biosciences of California, Inc. (NASDAQ

ACB) today announced financial results for its first quarter ended March 31, 2016.
PACB: 9.56 (-0.24)

Illumina's Gene Sequencers Are About to Revolutionize Healthcare
Motley Fool Staff - Motley Fool - Wed Apr 20, 7:21AM CDT
Over 7,500 of Illumina Corp 's gene sequencing machines are already being used by researchers globally to advance our understanding of DNA and DNA's relationship with disease. Discoveries stemming from this research are leading...
PACB: 9.56 (-0.24), TMO: 151.80 (-2.35), ILMN: 141.62 (-1.80)

Are Illumina's Shares Worth Buying on This Drop?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 5:21PM CDT
Image source: Illumina Inc. After the closing bell yesterday, Illumina 's management surprised investors with lackluster preliminary first-quarter sales that caused shares in the gene sequencing giant to plummet. With shares deeply discounted...
PACB: 9.56 (-0.24), TMO: 151.80 (-2.35), ILMN: 141.62 (-1.80)

Why Illumina Shares Are Tanking 18% Pre-Market
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 7:36AM CDT
SOURCE: ILLUMINA CORP What: After issuing preliminary revenue for the first quarter that was below industry watcher's targets, shares of Illumina are indicated to open lower by 18% today as of 8:30 a.m. EST. So what: The maker of machines...
PACB: 9.56 (-0.24), ILMN: 141.62 (-1.80)

What Awaits Pacific Biosciences (PACB) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 7:12AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report first-quarter 2016 results on Apr 21.
BDX: 169.29 (-0.94), PRXL: 60.16 (-1.54), PACB: 9.56 (-0.24), ALGN: 78.83 (-0.86)

Healthcare's Future: Science Fiction or Science Fact
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sat Apr 16, 11:03AM CDT
The potential to revolutionize healthcare is being driven by significant advances in technology that may improve patient procedures and usher in an era of personalized medicine. At the forefront of this innovation are Intuitive Surgica l's robotic...
ISRG: 641.59 (-6.61), PACB: 9.56 (-0.24), ILMN: 141.62 (-1.80), TRXC: 1.45 (+0.01)

Pacific Biosciences of California, Inc. First Quarter 2016 Financial Results Call
GlobeNewswire - Tue Apr 05, 4:18PM CDT
Pacific Biosciences of California, Inc. (NASDAQ

ACB) will hold its quarterly conference call to discuss its First Quarter 2016 Financial Results on Thursday, April 21, 2016, at 4:30pm Eastern Time.
PACB: 9.56 (-0.24)

14.1% Return Seen to Date on SmarTrend Pacific Biosciences of California Call (PACB)
Comtex SmarTrend(R) - Fri Apr 01, 1:43PM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ

ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 14.13% as of today's recent price of $9.21.
PACB: 9.56 (-0.24)

PacBio's SMRT Sequencing Provides Scientists with a Superior Gorilla Genome Reference
GlobeNewswire - Thu Mar 31, 1:00PM CDT
Pacific Biosciences of California, Inc., (Nasdaq

ACB) the pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT) technology, today announced that scientists from the University of Washington, the McDonnell Genome Institute at Washington University in St. Louis, and other institutions have published the best genome assembly of the gorilla to date -- more than 150-fold improvement over previous assemblies -- using long-read SMRT Sequencing from Pacific Biosciences. The peer-reviewed paper appears in the April 1 issue of the journal Science and is available online today.
PACB: 9.56 (-0.24)

Pacific Biosciences of California Shares Down 27.8% Since SmarTrend's Sell Call (PACB)
Comtex SmarTrend(R) - Thu Mar 24, 12:40AM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ

ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 27.83% as of today's recent price of $7.74.
PACB: 9.56 (-0.24)

Look for Shares of Pacific Biosciences of California to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Mon Mar 21, 4:54PM CDT
Pacific Biosciences of California (NASDAQ

ACB) traded in a range yesterday that spanned from a low of $8.27 to a high of $8.73. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $8.66 on volume of 505,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PACB: 9.56 (-0.24)

Is This the Biggest Threat Yet to Illumina?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 4:41PM CDT
IMAGE SOURCE: ILLUMINA INC. Illumina has held go-to status as the dominant maker of gene-sequencing devices for years, but a new, next-generation gene-sequencing machine made by Pacific Biosciences aims to change that. Can Illumina fend off...
PACB: 9.56 (-0.24), ILMN: 141.62 (-1.80)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Durability Over Comfort: Vibram's Global Footwear Shift

Durability Takes Center Stage in Footwear Choices Out with the fleeting, in with the durable! Vibram, that powerhouse in performance soles known for its little yellow octagon logo, is grabbing durability by the laces and pushing it to the forefront of the footwear game. With a freshly minted global survey shaking things up, turns out almost 8 in 10 of us aren't just...

HONOR2U Celebrates Veterans' Transition to Public Safety

Veterans Day Reflections Beyond the Battlefield You can hang up the uniform, but you can't hang up the call of duty. This Veterans Day, HONOR2U salutes those stepping off the battlefield right into our communities—trading military fatigues for public safety gear. They've swapped one uniform for another, and it's not just about new fibers; it's about carrying the torch...

Hexnode XDR Expands Threat Detection, MacOS Support

Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...

Decoding Renters vs. Homeowners Insurance Needs

Breaking Down Policy Differences If you've ever scratched your head over the insurance landscape, join the club. Renters and homeowners insurance each serve a specific role on the financial protection battlefield, and knowing what you're signing up for is downright vital. Oscar Salas from HelloNation lays out the core differences for anyone wise enough to get their heads...

Azenta's 2026 Gains Mask Deeper Challenges Ahead

Azenta's Financial Tangle in Fiscal 2026 You ever feel those moments when the numbers paint a pretty picture, but your gut knows there's more beneath? That's Azenta, Inc. (Nasdaq: AZTA) for fiscal 2026. We’re gazing at a revenue uplift of 5% year over year, hitting $622 million from continuing operations. Great, right? But dig deeper, and the tale isn't all sunshine and...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Leech Tishman Bolsters Entertainment Group with Key Hires

In the legal world, adding a couple of seasoned litigation heavyweights to a practice is akin to fortifying your castle before a siege. Leech Tishman, a national law firm, has just done that by bringing Bryan M. Sullivan and Zachary C. Hansen aboard to bolster their Entertainment & Sports Industry Group. With these additions, they're not just shoring up their defenses;...

Call for Biotech Shift: Scarcity Drives Urgency

The Cry for an Industrial Biotech Shift Alright, folks, here's the deal: James Michael Matthew is waving a red flag. He's saying it's time to overhaul our approach to industrial biotechnology. Why? Because we're up against some big-time raw material shortages. Matthew's call isn't just a whisper in the wind; it's a siren echoing through an industry teetering on the edge...

Sound Credit Union, WTA Team Up for Trail Support

Heading Into the Great Outdoors with Every Swipe You ever feel like your money's going nowhere useful? Well, folks in Washington are about to flip the script thanks to Sound Credit Union and the Washington Trails Association (WTA). They've cooked up a slick new money move—a co-branded debit and credit card program—where every swipe backs the state's beloved trails. A...